Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403444 | 1.00 | CYP19A1 (0.40) | CYP19A1HTR2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5632096 | 0.77 | RAB9A (0.49) | ALDH1A1SMN1; SMN2LMNACYP2C9CYP2C19 | |
| SCHEMBL6402488 | 0.77 | RAB9A (0.43) | HTR2AALDH1A1SMN1; SMN2LMNACYP2C9 | |
| SCHEMBL6402498 | 0.77 | RAB9A (0.43) | HTR2AALDH1A1SMN1; SMN2LMNACYP2C9 | |
| SCHEMBL5632091 | 0.77 | RAB9A (0.49) | ALDH1A1SMN1; SMN2LMNACYP2C9CYP2C19 | |
| SCHEMBL8371544 | 0.76 | MAPT (0.45) | ALDH1A1SMN1; SMN2LMNACYP2C9CYP2C19 | |
| SCHEMBL6410126 | 0.75 | MAOB (0.49) | CYP19A1HTR2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6410121 | 0.75 | MAOB (0.49) | CYP19A1HTR2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15038855 | 0.73 | HTR2A (0.43) | CYP19A1HTR2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5631835 | 0.70 | CTSB (0.48) | HTR2AALDH1A1SMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | CYP19A1 188/4885HTR2A 4216/4885ALDH1A1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.